SAINT LAURENT, Quebec, Oct. 9, 2012 (GLOBE NEWSWIRE) -- IntelGenx Corp. (IGX.V) (IGXT) ("IntelGenx", "the Company") today announced that Forfivo XL(TM) is now available by prescription in the USA.
Forfivo XL(TM) is indicated for treatment of Major Depressive Disorder (MDD) and is the only extended-release bupropion HCl product to provide a once-daily, 450mg dose in a single tablet. The active ingredient in Forfivo XL is bupropion, the same active ingredient used in the well-known antidepressant product: Wellbutrin XL(R). Until now, most patients in the US requiring a 450mg dose of bupropion have been taking multiple tablets to achieve their 450mg dose requirement. With Forfivo XL(TM) now available in the US, these patients can simplify their dosing regimen to a single Forfivo XL tablet, once-daily.
Loading more stuff…
Hmm…it looks like things are taking a while to load. Try again?